Durvalumab Plus Tremelimumab in Advanced Neuroendocrine Neoplasms: The DUNE Trial at ESMO 2020

A multi-cohort phase 2 study presented at ESMO 2020 evaluated the combination of durvalumab and tremelimumab in patients with advanced neuroendocrine neoplasms. The DUNE trial assessed the efficacy of this immunotherapy approach in various neuroendocrine tumor types, emphasizing the potential benefi

0 views • 17 slides